MedTrace Logo

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

NCT03199872 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-06-09

Study results available
· View outcomes & findings →

Summary

The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer

Conditions

Interventions

BIOLOGICAL

RV001V

Sc injection

Sponsors & Collaborators

  • Dantrials Aps

    collaborator INDUSTRY

  • RhoVac APS

    lead INDUSTRY

Principal Investigators

  • Jesper Sonne, MD, PhD · Dantrials Aps

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-30
Primary Completion
2018-08-01
Completion
2019-03-29

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199872 on ClinicalTrials.gov